In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

From US To EU: Young Biotechs Going It Alone

14 Nov 2022

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Topic Market Access Rare Diseases Strategy

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

20 Oct 2022

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

Topic Innovation Market Intelligence Research & Development

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Health Sector On High Alert As Wuhan Coronavirus Spreads

27 Nov 2020

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

Topic China Infectious Diseases Policy & Regulation Coronavirus

Medtech Insight: 世界の医療機器・医療技術の最新情報

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 1)

27 Nov 2020

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this first installment of a 10-part series, a procedure for hosting inspections is addressed.

Topic Compliance FDA

Medtech Insight: 世界の医療機器・医療技術の最新情報

CES 2020: Panel Discusses Health Care In 2040 – Empowered Consumer, Digital Transformation, Data Sharing, Open Source

27 Nov 2020

An expert panel at CES 2020 discussed Deloitte's vision for health care in 2040, with the empowered consumer managing their own health, enabled by a new ecosystem of secure, open access to data and "nudges" to change behaviors. Consulting firm Deloitte foresees outside disruptors dismantling the traditional health-care system, but panelists from Johnson & Johnson and Anthem flexed their muscles.

Topic Business Strategies Digital Health